Form 4: Cingulate Inc. Executive Matthew Brams Reports Stock Option Grant

EVP and Chief Medical Officer of Cingulate Inc., Matthew Brams, reports the acquisition of stock options.

Summary

• On March 4, 2024, Matthew Brams, the EVP and Chief Medical Officer of Cingulate Inc. (CING), was granted stock options to purchase 16,676 shares of common stock at an exercise price of $1.18.
• The options vest with 50% vesting on the six-month anniversary of the grant date, and the remaining shares vesting in substantially equal monthly installments over the following 30-month period.
• Following the transaction, Brams directly owns 16,676 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard executive compensation practice. It's neither overwhelmingly positive nor negative.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align executive interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term performance and commitment.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to improve company performance.
• Employees may see it as a positive sign of investment in leadership.

Key Dates

Keywords

stock options, Form 4, Cingulate Inc., Matthew Brams, executive compensation, beneficial ownership, CING